Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 49,898,000 | 48,677,000 | 46,099,000 | 50,135,000 | 49,436,000 |
| Cost of Goods | 15,121,000 | 14,425,000 | 14,510,000 | 17,175,000 | 17,520,000 |
| Gross Profit | 34,777,000 | 34,252,000 | 31,589,000 | 32,960,000 | 31,916,000 |
| Operating Expenses | 24,625,000 | 25,166,000 | 23,186,000 | 24,331,000 | 23,648,000 |
| Operating Income | 10,152,000 | 9,086,000 | 8,403,000 | 8,629,000 | 8,268,000 |
| Interest Expense | 869,000 | 850,000 | 932,000 | 777,000 | 707,000 |
| Other Income | 595,000 | 704,000 | 6,624,000 | 1,147,000 | 256,000 |
| Pre-tax Income | 9,878,000 | 8,940,000 | 14,095,000 | 8,999,000 | 7,817,000 |
| Income Tax | 1,807,000 | 1,793,000 | 1,295,000 | 1,296,000 | 1,119,000 |
| Net Income Continuous | 8,071,000 | 7,147,000 | 12,800,000 | 7,703,000 | 6,698,000 |
| Net Income Discontinuous | N/A | 4,590,000 | -186,000 | N/A | N/A |
| Minority Interests | -1,000 | 5,000 | 3,000 | 0 | 14,000 |
| Net Income | $8,072,000 | $11,732,000 | $12,611,000 | $7,703,000 | $6,684,000 |
| EPS Basic Total Ops | 3.55 | 5.12 | 5.44 | 3.28 | 2.82 |
| EPS Basic Continuous Ops | 3.54 | 3.12 | 5.52 | 3.28 | 2.82 |
| EPS Basic Discontinuous Ops | N/A | 2.00 | -0.08 | N/A | N/A |
| EPS Diluted Total Ops | 3.52 | 5.06 | 5.38 | 3.25 | 2.80 |
| EPS Diluted Continuous Ops | 3.52 | 3.08 | 5.46 | 3.25 | 2.79 |
| EPS Diluted Discontinuous Ops | N/A | 1.98 | -0.08 | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | 5.75 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $16,281,000 | $14,874,000 | $13,620,000 | $14,705,000 | $14,311,000 |